ERBB2-mutant tumors have a higher microsatellite instability (MSI) [13] and tumor mutation burden (TMB) than ERBB2 non-mutant tumors [1,2,5,14], suggesting that immune checkpoint inhibitors may be useful against ERBB2-mutant tumors [2,5,13]. Here, ERBB2 is linked to neoplasm.